Related references
Note: Only part of the references are listed.Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies
Ana-Maria Orbai et al.
RHEUMATOLOGY AND THERAPY (2021)
Tissue-Resident Memory CD8+T Cells From Skin Differentiate Psoriatic Arthritis From Psoriasis
Emmerik F. Leijten et al.
ARTHRITIS & RHEUMATOLOGY (2021)
New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies
Di Yan et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
The role of interleukin-17 in tumor development and progression
Junjie Zhao et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Targeting the interleukin-17 immune axis for cancer immunotherapy
Gerardo A. Vitiello et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients
Ana-Maria Orbai et al.
JOURNAL OF RHEUMATOLOGY (2020)
Polyfunctional, Proinflammatory, Tissue-Resident Memory Phenotype and Function of Synovial Interleukin-17A+CD8+T Cells in Psoriatic Arthritis
Kathryn J. A. Steel et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review
A. Al-Janabi et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Ixekizumab treatment of biologic-naive patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)
Vinod Chandran et al.
RHEUMATOLOGY (2020)
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review
April W. Armstrong et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel -group, randomised, active-controlled, phase 3b trial
Iain B. McInnes et al.
LANCET (2020)
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis
Frank Penkava et al.
NATURE COMMUNICATIONS (2020)
Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis
Bernard Combe et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis
Dafna Gladman et al.
RMD OPEN (2020)
The IL-17 Family of Cytokines in Health and Disease
Mandy J. McGeachy et al.
IMMUNITY (2019)
IL-17 receptor-based signaling and implications for disease
Xiaoxia Li et al.
NATURE IMMUNOLOGY (2019)
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2019)
Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis
Dafna D. Gladman et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
Desiree van der Heijde et al.
JOURNAL OF RHEUMATOLOGY (2018)
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naive patients with active psoriatic arthritis (SPIRIT-P1)
Alice B. Gottlieb et al.
RHEUMATOLOGY (2018)
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2
Mark C. Genovese et al.
RHEUMATOLOGY (2018)
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
Peter Nash et al.
RMD OPEN (2018)
International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials
Ana-Maria Orbai et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash et al.
LANCET (2017)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C. Coates et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set
Umut Kalyoncu et al.
RMD OPEN (2016)
Interleukin-17+CD8+T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression
Bina Menon et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Th17 and Th22 cells in psoriatic arthritis and psoriasis
Helen Benham et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Classification criteria for psoriatic arthritis - Development of new criteria from a large international study
William Taylor et al.
ARTHRITIS AND RHEUMATISM (2006)
Share Paper
